Dyax Corp. (NASDAQ:DYAX), a completely integrated biopharmaceutical company, recently announced Todd Bazemore as the new Chief Commercial Officer. Todd Bazemore has been appointed as the executive vice president as well as the chief commercial officer of the company. The newly appointed CCO and Executive VP will be responsible in leading the company’s commercial organization which markets KALBITOR® for the treatment of attacks of hereditary angioedema. Dyax Corp. (NASDAQ:DYAX) shares after opening at $6.56 moved to $7.00 on last trade day and at the end of the day closed at $6.51. Company price to sales ratio in past twelve months was calculated as 16.40 and price to cash ratio as 7.93. Dyax Corp. (NASDAQ:DYAX) showed a negative weekly performance of -2.84%.
XOMA Corp (NASDAQ:XOMA) has been using its important drug gevokizumab which was earlier called as XOMA 052, which is a humanized monoclonal allosteric which is used in modulating antibody design to inhibit pro-inflammatory cytokine. XOMA Corp (NASDAQ:XOMA) shares fell -3.54% in last trading session and ended the day on $3.82. XOMA return on assets is -152.10%. XOMA Corp (NASDAQ:XOMA) yearly performance is 10.09%.
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) Net loss for the fourth quarter of 2013 was $8.9 million, or $(0.09) per share, compared to a net loss of $30.2 million, or $(0.37) per share, for the fourth quarter of 2012. Included in the loss for the fourth quarter of 2013 was a non-cash expense of $1.8 million compared to a non-cash gain of $8.6 million for the fourth quarter of 2012. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) shares moved down -1.79% in last trading session and was closed at $3.29, while trading in range of $3.10 – $3.48. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) year to date (YTD) performance is -24.19%.
Inovio Pharmaceuticals Inc. (NYSEMKT:INO) on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Biotechnology industry. The net income has significantly decreased by 2245.1% when compared to the same quarter one year ago, falling from -$0.66 million to -$15.45 million. Inovio Pharmaceuticals Inc. (NYSEMKT:INO) weekly performance is -9.34%. On last trading day company shares ended up $2.33. Inovio Pharmaceuticals Inc. (NYSEMKT:INO) distance from 50-day simple moving average (SMA50) is -27.15%. Analysts mean target price for the company is $5.00.